Suven Life Sciences Ltd

Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical firm dedicated to the acquisition, advancement, and global commercialization of innovative therapies. Operating across India, the United States, Europe, and other international markets, the company primarily concentrates on neurodegenerative disorders, particularly through the discovery and advancement of novel chemical entities (NCEs) for central nervous system (CNS) conditions. Its current pipeline features several promising product candidates, including Masupirdine (SUVN-502) for Alzheimer's disease and related neuropsychiatric symptoms. Other key developments include Samelisant (SUVN-G3031), a potent and selective histamine H3 receptor inverse agonist addressing sleep and cognitive disorders, and Ropanicant (SUVN-911), a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist aimed at depressive disorders. Additionally, Suven is progressing Usmarapride (SUVN-D4010), a potent, selective, orally bio-available, and brain-penetrant 5-HT4 receptor partial agonist for cognitive disorders; SUVN-I6107, also for cognitive disorders; SUVN-M8036 for psychiatric conditions; and SUVN-D1044 for gastrointestinal ailments. Established in 1989 as Suven Pharmaceuticals Pvt. Ltd., the company adopted its present name in 2003. Headquartered in Hyderabad, India, Suven Life Sciences Limited functions as a subsidiary of Jasti Property and Equity Holdings Private Limited.